EU Medical Devices Trade with Switzerland after the Implementation of the MDR
The new EU regulation on medical devices (EU-MDR) has been enforced since May 26, 2021. However, Switzerland is not an EU Member State, which means it is considered a third country according to the new EU-MDR. This entails consequences for the trade of CE-marked medical devices between Switzerland and the EU.

SWITZERLAND AS A THIRD COUNTRY

Switzerland is located in Europe, but it is not an European Union (EU) Member State. It is part of the European Free Trade Association (EFTA) and belongs to the European Economic Area (EEA). EFTA has no legal obligation to follow EU product legislation and trade with Switzerland is established via multiple mutual recognition agreements.

Until now, there was a Mutual Recognition Agreement (MRA) between Switzerland and the EU for the Medical Devices Directive (MDD) and Active Implantable Devices Directive (AIMDD), which allowed medical devices (and other products like machinery and motor vehicles) to move freely between this country and the European Union Market. The EU-Switzerland MRA has previously recognized conformity assessment certificates between the EU and Switzerland based on equivalent regulations. It falls under the scope of the EU-Switzerland Institutional Framework Agreement (InstA) that has been in negotiation between the EU and Switzerland since 2014.

However, this MRA ended because the MDD and AIMDD are no longer applicable and the MRA was not updated. With the full application of the EU Medical Device Regulation (MDR – Regulation (EU) 2017/745, explained in our previous post) on May 26 this year, Switzerland became officially a “third country” to the effects of the EU-MDR. The EU has stated that in the absence of a deal regarding the implementation of the InstA, a full update of the MRA (including the medical devices chapter) cannot be considered.

The MRA has not been updated but it has not been withdrawn, so the EU Directive 98/79/EC on in vitro diagnostic medical devices (IVDD) remains mutually recognized. In 2022 (May 26th), the IVDD will be replaced by the Regulation (EU) 2017/746 (IVDR) and, in the absence of an updated MRA, in vitro medical devices will no longer be covered by the MRA, therefore happening the same as with the non-in vitro medical devices.

CONSEQUENCES IN THE TRADE WITH SWITZERLAND

Until a potential agreement on the proposed modification to the MRA is reached, the trade facilitating effects of the MRA for medical devices falling under the new MDR cease to apply. As a result, this has consequences, particularly when it comes to the mutual recognition of conformity assessment results, the need for an authorized representative and the alignment of technical regulations.

The Swiss Federal Council adopted on May 19th 2021 an amendment to the Swiss Ordinance on Medical Devices (MedDO). This amendment introduces additional requirements to account for the absence of an updated MRA, establishing conditions for trade of medical devices which are covered by EU issued certificates on the Swiss market. The existing certificates (issued under the MRA) by conformity assessment bodies established in the EU are recognized and transitional timelines are granted for the designation of a representative in Switzerland for EU/EEA medical devices manufacturers.

Swiss medium and high-risk devices must be certified by conformity assessment bodies established in the EU. The existing certificates (issued under the MRA) issued by conformity assessment bodies established in Switzerland will no longer be recognized. Switzerland is disputing this EU unilateral determination and defends that transition periods should be given.

Swiss manufacturers, treated now as third country manufacturers, need to appoint a European Authorized Representative so they can export their devices to Europe. On the other hand, European manufacturers must designate a Swiss Authorized Representative to export their products to Switzerland, complying with the Medical Device Ordinance (MedDO). According to the revised MedDO, a Swiss Authorized Representative is “any natural or legal person established within Switzerland who has received a written mandate from a manufacturer located in another country to act on the manufacturer’s behalf in relation to specified tasks with regard to the latter’s obligation under this Ordinance”. A Swiss Authorized Representative is required for all medical devices, except for in-vitro medical devices (which are not concerned by the revised MedDO), all procedure packs and all systems.

Economic operators (manufacturers, importers, and authorized representatives) must register with Swissmedic in order to obtain an unique identification number (“Swiss Single Registration Number” – CHRN), within 3 months after placing a device on the market. EUDAMED (EU database on medical devices – see previous post) is not accessible to Swissmedic.

There is still a lot of uncertainty involving the medical devices trade between Switzerland and the EU and how it is going to unfold. One thing is sure, without and updated MRA, Switzerland is regarded as a third country to the effects of the EU MDR and EEA countries are third countries under the Swiss legislation on medical devices.

Critical Catalyst will continue to monitor this situation, assisting Medical Devices companies in the best way possible. If you wish to get more information on this matter or place any questions to our regulatory team, do not hesitate to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices. Available at: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02017R0745-20200424&from=EN
  2. Commission published information notice on the status of the EU-Switzerland Mutual Recognition Agreement for Medical Devices. 26 May 2021. European Commission. Available at: https://ec.europa.eu/commission/presscorner/detail/en/IP_21_2684

further
reading

cosmetic products

May Butylphenyl Methylpropional be used in Cosmetic Products?

Butylphenyl Methylpropional, also known as Lilial, is a fragrance ingredient that has been used for years in several cosmetic and non-cosmetic products. Nevertheless, some concerns have been expressed regarding the use of this ingredient and its risk to consumers. According to an amendment to the CLP Regulation, the use of Butylphenyl Methylpropional will be prohibited in cosmetic products from 1st March 2022.

Read More »
cosmetic products

How are Cosmetic Products Regulated in the United Arab Emirates?

The United Arab Emirates (UAE) are an emerging market for the beauty industry. Cosmetics and personal care products supplied or sold in the UAE must comply with the health and safety requirements set out in UAE legislation. Overall, the process for importing a cosmetic product into the UAE market from the European Union can be quite straightforward since the UAE has aligned several of its requirements with the European Cosmetic Regulation.

Read More »
cosmetic products

European Commission Report on Nanomaterials – 2021

The European Commission is required to submit to the European Parliament and the Council an annual status report on the use of nanomaterials in cosmetic products and to review the provisions concerning nanomaterials in the European Regulation (EC) No 1223/2009 on cosmetic products. In July 2021, the Commission has issued its latest annual report on this subject.

Read More »
cosmetic products

New Labelling Requirements for Cosmetic Products in China

The new Cosmetics Supervision and Administration Regulation (CSAR) was enacted in China. The National Medical Products Administration (NMPA) has released standards for the testing of cosmetic products’ safety profile and efficacy claims. The NMPA has also published the Administrative Measures on Cosmetics Labelling, an updated set of requirements for the label of cosmetic products made available in the Chinese market.

Read More »
cosmetic products

50th Amendment to the IFRA Code of Practice

On June 30, IFRA announced the notification of the 50th Amendment to the IFRA Standards. The Standards form the basis for the globally accepted and recognized risk management system for the safe use of fragrance ingredients and are part of the IFRA Code of Practice. The amendment introduced one update to the Standards and one new prohibited substance – Mintlacton.

Read More »
medical devices

EN ISO 13485:2016 – Amendment 11 has been published!

The European standardisation bodies CEN and CENELEC published EN ISO 13485:2016+A11:2021 featuring new annexes ZA and ZB that link the requirements of the MDR (Regulation EU 2017/745) and the IVDR (Regulation EU 2017/746), respectively, to specific clauses of the standard.

Read More »
cosmetic products

How are Cosmetic Products Regulated in India?

The different expectations and needs of consumers are continually changing and therefore the cosmetic industry needs to be gradually evolve to meet the new consumer’s demand. In this regard, India has recently introduced some regulatory updates to ensure that cosmetics placed on the market are safer for all consumers.

Read More »
cosmetic products

Is Phenoxyethanol Safe for Use in All Cosmetic Products?

Phenoxyethanol is a common preservative used in cosmetic and personal care products worldwide. It has been subject to various safety assessments and most concluded about its safety under the current most frequent uses. Nevertheless, some concerns were raised by the French Agency ANSM, particularly regarding its use in products intended for the nappy area in children up to 3 years old.

Read More »
cosmetic products

Cannabis-Derived Ingredients in Cosmetic Products

Cannabis-derived ingredients are popular compounds with interesting properties. There is specific EU and national legislation regarding cannabis-derived ingredients, identifying which extracts and derivatives may be used in cosmetic products. There are several aspects to consider to ensure compliance when adding these compounds to cosmetics and personal care products.

Read More »
cosmetic products

Cosmetic Products Testing in the European Union

A cosmetic product which is made available on the European Union market needs to prove that it is safe for consumers. Apart from the mandatory testing, depending on the claims to be used or the type of cosmetic product to be placed on the market, additional tests may be required.

Read More »
COVID-19

New EU Commission Recommendation for PPE and Medical Devices – COVID-19

PPE and Medical Devices have proven to be essential for healthcare workers in the efforts to contain the COVID-19 outbreak. In March 2020, the EU Commission urged the economic operators to increase rapid supply into the market. Currently, the Commission considers that the conditions for exceptional access to market are no longer met, limiting the placing of PPE and Medical Devices which have not successfully undergone the relevant conformity assessment procedures applicable on the EU market.

Read More »